Cumberland Partners Ltd Acquires 19,130 Shares of AbbVie Inc. $ABBV

Cumberland Partners Ltd boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 76.2% in the third quarter, Holdings Channel.com reports. The fund owned 44,232 shares of the company’s stock after buying an additional 19,130 shares during the quarter. Cumberland Partners Ltd’s holdings in AbbVie were worth $10,241,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new position in AbbVie during the second quarter valued at approximately $28,000. Redmont Wealth Advisors LLC bought a new stake in AbbVie in the third quarter valued at approximately $41,000. Financial Gravity Companies Inc. bought a new stake in AbbVie in the second quarter valued at approximately $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in AbbVie in the second quarter worth $39,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $228.79 on Thursday. The stock has a market capitalization of $404.36 billion, a P/E ratio of 96.95, a P/E/G ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The business has a 50-day moving average of $224.01 and a 200-day moving average of $221.68.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. JPMorgan Chase & Co. boosted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.56.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.